13. 多発性硬化症/視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


臨床試験数 : 3,342 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

  
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05007483
(ClinicalTrials.gov)
March 1, 20229/8/2021Efficacy of Diet on Quality of Life in Multiple SclerosisEfficacy of Diet on Quality of Life in Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingDietary Supplement: BodyBio Balance Oil;Dietary Supplement: Kirunal Fish Oil;Dietary Supplement: BodyBio PC;Behavioral: Modified Paleolithic Elimination diet;Behavioral: Time Restricted Olive Oil Based (TROO) Ketogenic Diet;Behavioral: Dietary Guidelines for Americans DietTerry L. WahlsNULLNot yet recruiting18 Years70 YearsAll156N/AUnited States
2EUCTR2015-003147-19-GR
(EUCTR)
18/07/201625/05/2016To confirm the safety and efficacy of NEUROASPIS PLP10® in the treatment of individuals, who have been diagnosed with relapsing remitting multiple sclerosis (MS).Novel Oral Nutraceutical Intervention NEUROASPIS PLP10® for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Multicenter, Parallel-group, Phase III, Double-blind, Randomized, Placebo-Controlled, Add-on with Interferon Beta, Trial of Efficacy and Safety. - Efficacy and Safety study of NEUROASPIS PLP10® versus placebo Relapsing-Remitting Multiple Sclerosis (RRMS)
MedDRA version: 19.0;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: NEUROASPIS PLP10®
INN or Proposed INN: FISH OIL,RICH IN OMEGA 3 ACIDS
Other descriptive name: FISH OIL, RICH IN OMEGA-3-ACIDS
INN or Proposed INN: BORAGE OIL 20% GLA
Other descriptive name: BORAGE OIL
INN or Proposed INN: beta-Carotene
Other descriptive name: BETACAROTENE
INN or Proposed INN: Gamma-tocopherol
PALUPA Medical LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
220Phase 3Greece
3NCT02939079
(ClinicalTrials.gov)
April 201514/10/2016Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis PatientsEvaluating the Effect of Fingolimod With Fish Oil Compared to Fingolimod With Placebo on Tumor Necrosis Factor-a , Interleukin1b , Interleukin6, and Interferon-gamma in Patients With Relapsing-Remitting Multiple SclerosisMultiple SclerosisDrug: Fingolimod;Dietary Supplement: Fish Oil;Drug: Placebo (for Fish Oil)Isfahan University of Medical SciencesShiraz University of Medical SciencesCompleted18 Years45 YearsAll50Phase 2/Phase 3NULL
4NCT01842191
(ClinicalTrials.gov)
May 201025/4/2013Efficacy of Fish Oil in Multiple SclerosisEfficacy of Fish Oil on Serum TNFa, IL-1ß, IL-6, Oxidative Stress Markers in Multiple Sclerosis Treated With Interferon Beta 1-bRelapsing- Remitting Multiple SclerosisDietary Supplement: Fish Oil;Dietary Supplement: PlaceboCoordinación de Investigación en Salud, MexicoNULLCompleted18 Years55 YearsBoth50Phase 4Mexico
5NCT00676156
(ClinicalTrials.gov)
December 20057/5/2008A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple SclerosisA Pilot Trial to Study the Pharmacokinetics of Oral Lipoic Acid (LA) and Immunological Effects of LA in Multiple SclerosisMultiple SclerosisDrug: oral lipoic acid (LA);Drug: lipoic acid (LA) with fish oil and LA without fish oil;Drug: R lipoic acidOregon Health and Science UniversityNational Center for Complementary and Integrative Health (NCCIH)Completed18 Years80 YearsBoth40Phase 1United States
6NCT00122954
(ClinicalTrials.gov)
July 200520/7/2005Fish Oil for the Treatment of Depression in Patients With Multiple SclerosisFish Oil as an Adjunct Therapy for Depression in Multiple SclerosisMultiple Sclerosis;DepressionDrug: Fish oil concentrate;Drug: PlaceboOregon Health and Science UniversityNational Center for Complementary and Integrative Health (NCCIH)Completed18 Years85 YearsAll39Phase 1/Phase 2United States